EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example

Xian Pan iD, Khaled Abduljalil iD, Lisa M Almond iD, Amita Pansari iD, Karen Rowland Yeo iD

CPT: Pharmacometrics & Systems Pharmacology · 2024-03 · 13 (3) · 386-395

DOI: 10.1002/psp4.13090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 12.12.2023. Verfasst von Xian Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Limited (Simcyp Division), Sheffield, UK. Hauptthemen laut MEDLINE: Lactation, Primaquine. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evaluating the safety of primaquine (PQ) during breastfeeding requires an understanding of its pharmacokinetics (PKs) in breast milk and its exposure in the breastfed infant. Physiologically‐based PK (PBPK) modeling is primed to assess the complex interplay of factors affecting the exposure of PQ in both the mother and the nursing infant. A published PBPK model for PQ describing the metabolism by monoamine oxidase A (MAO‐A; 90% contribution) and cytochrome P450 2D6 (CYP2D6; 10%) in adults was applied to predict the exposure of PQ in mothers and their breastfeeding infants. Plasma exposures following oral daily dosing of 0.5 mg/kg in the nursing mothers in a clinical lactation study were accurately captured, including the observed ranges. Reported infant daily doses based on milk data from the clinical study were used to predict the exposure of PQ in breastfeeding infants greater than or equal to 28 days. On average, the predicted exposures were less than or equal to 0.13% of the mothers. Furthermore, in simulations involving neonates less than 28 days, PQ exposures remain less than 0.16% of the mothers. Assuming that MAO‐A increases slowly with age, the predicted relative exposure of PQ remains low in neonates (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LactationPrimaquineInfantInfant, NewbornAdultChildFemaleHumansMothersBreast FeedingCytochrome P-450 CYP2D6Monoamine Oxidase

Substanzen

PrimaquineCytochrome P-450 CYP2D6Monoamine Oxidase

Autor:innen und Institutionen

  • Certara UK Limited (Simcyp Division), Sheffield, UK.

ORCID-Profile: Xian Pan, Khaled Abduljalil, Lisa M Almond, Amita Pansari, Karen Rowland Yeo

Zitieren

APA

Pan, X., Abduljalil, K., Almond, L. M., Pansari, A., & Yeo, K. R. (2024). Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example. CPT: Pharmacometrics & Systems Pharmacology, 13(3), 386-395. https://doi.org/10.1002/psp4.13090

Vancouver

Pan X, Abduljalil K, Almond LM, Pansari A, Yeo KR. Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(3):386-395. doi:10.1002/psp4.13090

BibTeX
@article{Pan2024,
  author = {Pan, Xian and Abduljalil, Khaled and Almond, Lisa M and Pansari, Amita and Yeo, Karen Rowland},
  title = {Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {3},
  pages = {386--395},
  doi = {10.1002/psp4.13090}
}
Kostenlos starten →